Corbus Pharmaceuticals

Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)

Antonette Ho2024-10-26T09:34:15-04:00Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a diversified portfolio, announced today that it has completed enrollment of the dose escalation part of its bridging Phase 1 clinical trial of CRB-701 (SYS6002). The dose escalation part of this open label study (NCT06265727) is being conducted in the US and the UK. The three-part Phase 1 trial is evaluating the safety, pharmacokinetics and efficacy of CRB-701 in patients with advanced solid tumors...

Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC

Antonette Ho2024-04-06T15:17:16-04:00Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, announced today the first patient in the U.S. has been dosed in the Phase 1 clinical trial of CRB-701 (SYS6002), a next-generation antibody-drug-conjugate (ADC) targeting Nectin-4. The Phase 1 portion of the open label study design (NCT06265727), being conducted in the U.S. and Europe, will evaluate the safety, efficacy and pharmacokinetics (PK) of CRB-701 in participants with advanced solid tumors associated with...

Corbus Pharmaceuticals Names Dominic Smethurst CMO

Antonette Ho2024-03-10T00:38:38-05:00Corbus Pharmaceuticals Holdings, Inc. (CRBP) Wednesday announced that it has appointed Dominic Smethurst as its chief medical officer. Smethurst has over 20 years of experience in the pharmaceutical and biotechnology sector, including the UK's National Health Service. Most recently he was the CMO of Bicycle Therapeutics. In pre-market activity, Corbus shares are trading at $26.75, up 2.61% on the Nasdaq. Read more >>

Corbus Pharmaceuticals Announces Pricing of Public Offering

Antonette Ho2024-02-02T16:08:54-05:00Corbus Pharmaceuticals Holdings, Inc., a precision oncology company with a diversified portfolio, today announced the pricing of an underwritten public offering of 4,325,000 shares of its common stock at a public offering price of $19.00 per share, for a total public offering size of approximately $82.2 million, before deducting underwriting discounts and estimated offering expenses. In addition, Corbus has granted the underwriters a 30-day option to purchase up to an additional 648,750 shares of its common stock on the same...

Corbus Pharma’s IND Application Gets FDA Clearance For Investigational Drug CRB-601

Antonette Ho2024-01-18T20:38:09-05:00Corbus Pharmaceuticals Holdings, Inc.  Tuesday announced FDA clearance for its investigational new drug or IND application of CRB-601, a TGFß blocking monoclonal antibody targeting the integrin avß8. Read more >>

Corbus Pharmaceuticals expands oncology pipeline with the addition of a clinical stage Nectin-4 targeting Antibody Drug Conjugate (ADC)

Antonette Ho2023-02-14T20:04:38-05:00Corbus Pharmaceuticals Holdings, Inc., a precision oncology company, today announced that it has entered into an exclusive licensing agreement with CSPC Megalith Biopharmaceutical Co., Ltd, a subsidiary of CSPC Pharmaceutical Group Limited (CSPC; HKEX: 01093) for development and commercialization of CRB-701 (SYS6002): a novel clinical stage antibody drug conjugate (ADC) targeting Nectin-4. The agreement covers exclusive commercialization rights to CRB-701 in the United States, Canada, the European Union (including the European Free Trade Area), the United Kingdom, and Australia. CSPC...

Corbus Pharmaceuticals Appoints Anne Altmeyer, PhD to Board of Directors

Ziad2022-11-25T13:59:44-05:00Corbus Pharmaceuticals Holdings, Inc., an immunology company, today announced the appointment of Anne Altmeyer, PhD, MBA, MPH to its board of directors. Read more >>

Corbus Pharmaceuticals Appoints Rachael Brake, Ph.D., as Chief Scientific Officer

Ziad2022-11-25T14:00:10-05:00Corbus Pharmaceuticals Holdings, Inc. today announced the appointment of Rachael Brake, Ph.D., as Chief Scientific Officer, furthering the Company's mission of connecting innovation to purpose. Dr. Brake will build upon Corbus' commitment to immuno-oncology and joins the Company following the recent acquisition of monoclonal antibodies that inhibit TGFβ activation. Dr. Brake formerly held leadership roles at Takeda Oncology, including Vice President, Global Project Leader in the Oncology Therapeutic Area and Head, U.S. Medical Affairs, Oncology Business Unit.

Corbus Pharmaceuticals Expands Pipeline with Two New mAbs

Ziad2022-11-25T14:00:29-05:00 Corbus Pharmaceuticals has licensed two integrin-targeting mAbs, expanding its therapeutics pipeline into inflammatory, fibrotic, and metabolic diseases as well as cancer. Read more >>

Corbus Pharmaceuticals Licenses Two Integrin Targeting mAbs Further Expanding Pipeline into Cancer and Fibrotic Diseases

Ziad2022-11-25T14:00:30-05:00 Corbus diversifies pipeline with two new mAbs that target integrins that inhibit activation of TGFβ. High potency anti-αvβ8 mAb licensed from University of California San Francisco andanti-αvβ6/αvβ8 mAb licensed from Panorama Research Inc. Both mAbs expected to start Phase 1 testing in 2022. Capital and resources in place to advance multiple programs into clinical development. Read more >>